Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats

Basit Öğe Kaydı
dc.authorid0000-0001-6494-8923
dc.contributor.authorEren, Zehra
dc.contributor.authorGünal, Mehmet Yalçın
dc.contributor.authorArı Bakır, Elif
dc.contributor.authorÇoban, Jale
dc.contributor.authorÇaglayan, Berrak
dc.contributor.authorEkimci, Nur
dc.contributor.authorEthemoğlu, Sinem
dc.contributor.authorAlbayrak, Özgür
dc.contributor.authorAkdeniz, Tuba
dc.contributor.authorYanıkkaya Demirel, Gülderen
dc.contributor.authorKılıç, Ertugrul
dc.contributor.authorKantarcı, Gülçin
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:01:35Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:01:35Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Fizyoloji Ana Bilim Dalı
dc.descriptionWOS: 000347728100009
dc.descriptionPubMed ID: 25532067
dc.description.abstractBackground/Aims: The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats. Methods: Forty male Sprague Dawley rats were divided into 5 groups of 8 rats each, namely the control (Group C), diabetes (Group D), aliskiren (Group A), paricalcitol (Group P), and aliskiren plus paricalcitol (Group A+P) groups. Aliskiren was given by oral-gavage at a dose of 50 mg/kg/day once daily for 12 weeks. Paricalcitol was given by intraperitoneally at a dose of 0,4 mu g/kg/three day of week for 12 weeks. Renal function parameters, oxidative stress biomarkers, mRNA expression of renin-angiotensin system parameters and kidney histology were determined. Results: Group A+P had lower mean albumin-to-creatinine ratio (ACR) (p=0.004) as well as higher creatinine clearance (CCr) (p<0.005) than the diabetic rats (Group D). Combination therapy significantly increased CCr (Group A+P vs Group A, p<0.005; Group A+P vs Group P, p=0.022) and reduced ACR (Group A+P vs Group A, p=0.018; Group A+P vs Group P, p<0.005) when compared to monotherapy. Serum malondialdehyde levels were significantly lower (p=0.004); glutathion levels (p=0.003), glutathion peroxidase (p=0.004) and superoxide dismutase (p<0.005) activities were significantly higher in group A+P than in group D. The mean scores of mRNA expression of renin (p<0.005), angiotensin II (p=0.012) and angiotensin type 1 receptor (p=0.018) in group A+P were significantly lower. Although combination therapy showed no additional effect on oxidative system, renin-angiotensin system and renal histology, aliskiren plus paricalcitol significantly decreased interstitial fibrosis volume when compared to monotherapy (Group A+P vs Group A, p<0.005; Group A+P vs Group P, p=0.002). Conclusion: Our data seem to suggest a potential role of aliskiren plus paricalcitol acting synergystically for reducing the progression of diabetic nephropathy in an experimental rat model.
dc.description.sponsorshipScientific and Technical Research Council of Turkey [TUBITAK 111S299]en_US
dc.description.sponsorshipThis work was supported by The Scientific and Technical Research Council of Turkey (TUBITAKTUBITAK SBAG 111S299). The authors would like to acknowledge the contributions of Prof. Dr. Mujdat Uysal. We thank Burak Caglayan and Mustafa Caglar Beker for expert technical assistance.en_US
dc.identifier.citationEren, Z., Günal, M. Y., Arı Bakır, E., Çoban, J., Çaglayan, B., Ekimci, N. ... Kantarcı, G. (2014). Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats. Kidney and Blood Pressure Research, 39(6), 581-590. https://dx.doi.org/10.1159/000368471
dc.identifier.doi10.1159/000368471
dc.identifier.endpage590
dc.identifier.issn1420-4096
dc.identifier.issn1423-0143
dc.identifier.issue6
dc.identifier.scopusqualityQ2
dc.identifier.startpage581
dc.identifier.urihttps://dx.doi.org/10.1159/000368471
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3357
dc.identifier.volume39
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofKidney and Blood Pressure Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.tubitakinfo:eu-repo/grantAgreement/TUBITAK/SOBAG/111S299
dc.rightsAttribution-NonCommercial 3.0 Unported*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/*
dc.subjectAliskiren
dc.subjectDiabetic Nephropathy
dc.subjectParicalcitol
dc.titleEffects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kilic, Ertugrul-2014.pdf
Boyut:
2.86 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu